ES2987696T3 - Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón - Google Patents
Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón Download PDFInfo
- Publication number
- ES2987696T3 ES2987696T3 ES19185833T ES19185833T ES2987696T3 ES 2987696 T3 ES2987696 T3 ES 2987696T3 ES 19185833 T ES19185833 T ES 19185833T ES 19185833 T ES19185833 T ES 19185833T ES 2987696 T3 ES2987696 T3 ES 2987696T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- polynucleotide
- subject
- cancer
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168449P | 2015-05-29 | 2015-05-29 | |
| US201562168470P | 2015-05-29 | 2015-05-29 | |
| US201562169321P | 2015-06-01 | 2015-06-01 | |
| US201562169309P | 2015-06-01 | 2015-06-01 | |
| US201662276767P | 2016-01-08 | 2016-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2987696T3 true ES2987696T3 (es) | 2024-11-15 |
Family
ID=56098419
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19185833T Active ES2987696T3 (es) | 2015-05-29 | 2016-05-23 | Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón |
| ES16727089T Active ES2752063T3 (es) | 2015-05-29 | 2016-05-23 | Administración intrapulmonar de agonistas polinucleotídicos del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16727089T Active ES2752063T3 (es) | 2015-05-29 | 2016-05-23 | Administración intrapulmonar de agonistas polinucleotídicos del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9993495B2 (https=) |
| EP (2) | EP3302502B1 (https=) |
| JP (1) | JP6792294B2 (https=) |
| KR (1) | KR102779525B1 (https=) |
| CN (1) | CN107708706A (https=) |
| AU (1) | AU2016270782B2 (https=) |
| CA (1) | CA2987237A1 (https=) |
| DK (1) | DK3302502T3 (https=) |
| ES (2) | ES2987696T3 (https=) |
| HK (1) | HK1251471A1 (https=) |
| IL (1) | IL255903B (https=) |
| MX (1) | MX381587B (https=) |
| RU (1) | RU2017145940A (https=) |
| WO (1) | WO2016196062A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| JP6991857B2 (ja) * | 2014-10-10 | 2022-01-13 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療 |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| KR102779525B1 (ko) * | 2015-05-29 | 2025-03-12 | 다이나박스 테크놀로지 코퍼레이션 | 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| MX2019002925A (es) | 2016-09-15 | 2019-09-05 | Idera Pharmaceuticals Inc | Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| WO2020081398A1 (en) * | 2018-10-14 | 2020-04-23 | Dynavax Technologies Corporation | Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer |
| KR20210079319A (ko) * | 2018-10-18 | 2021-06-29 | 도이체스 크렙스포르슝스첸트룸 | 흡입용 건조 약학적 조성물 |
| CN111321159B (zh) * | 2018-12-14 | 2023-12-12 | 中天(上海)生物科技有限公司 | 用于免疫调节的嵌合核酸分子及其应用 |
| US20220370606A1 (en) * | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| WO2021007160A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| TWI833056B (zh) * | 2019-12-31 | 2024-02-21 | 財團法人工業技術研究院 | 核酸藥物複合體以及其用途 |
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| CN114099535B (zh) * | 2020-12-10 | 2023-01-03 | 南京吉迈生物技术有限公司 | Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物 |
| WO2022140661A1 (en) * | 2020-12-23 | 2022-06-30 | Cascade Prodrug Inc. | Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor |
| US20250009731A1 (en) | 2021-11-08 | 2025-01-09 | Nurix Therapeutics, Inc. | Toll-like receptor therapy combinations with cbl-b inhibitor compounds |
| WO2023141599A2 (en) * | 2022-01-21 | 2023-07-27 | Trisalus Life Sciences, Inc. | Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists |
| WO2024186193A1 (ko) * | 2023-03-08 | 2024-09-12 | 인제대학교 산학협력단 | 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU760549B2 (en) * | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| WO1999060166A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
| KR100881923B1 (ko) | 2000-12-27 | 2009-02-04 | 다이나박스 테크놀로지 코퍼레이션 | 면역자극 폴리뉴클레오티드 및 그것의 사용 방법 |
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| AU2003281200A1 (en) * | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| JP5102959B2 (ja) * | 2002-12-23 | 2012-12-19 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激配列オリゴヌクレオチド及びその使用方法 |
| JP2007526253A (ja) * | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 免疫刺激性ウイルスｒｎａオリゴヌクレオチド |
| CN101134046B (zh) * | 2006-09-01 | 2011-10-05 | 中国医学科学院药物研究所 | Tlr4和tlr9激动剂复方在抑制肿瘤转移中的应用 |
| EP2391718A2 (en) * | 2009-01-30 | 2011-12-07 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| WO2012156817A2 (en) * | 2011-05-19 | 2012-11-22 | Teva Pharmaceutical Industries Ltd. | Method for treating non-small cell lung cancer |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| MX2017015311A (es) * | 2015-05-29 | 2018-06-19 | Merck Sharp & Dohme | Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer. |
| KR102779525B1 (ko) | 2015-05-29 | 2025-03-12 | 다이나박스 테크놀로지 코퍼레이션 | 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여 |
| SG11201808913WA (en) * | 2016-04-15 | 2018-11-29 | Dynavax Tech Corp | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer |
-
2016
- 2016-05-23 KR KR1020177035856A patent/KR102779525B1/ko active Active
- 2016-05-23 CN CN201680031295.6A patent/CN107708706A/zh active Pending
- 2016-05-23 DK DK16727089T patent/DK3302502T3/da active
- 2016-05-23 EP EP16727089.1A patent/EP3302502B1/en active Active
- 2016-05-23 CA CA2987237A patent/CA2987237A1/en active Pending
- 2016-05-23 ES ES19185833T patent/ES2987696T3/es active Active
- 2016-05-23 HK HK18110977.6A patent/HK1251471A1/zh unknown
- 2016-05-23 AU AU2016270782A patent/AU2016270782B2/en active Active
- 2016-05-23 JP JP2017561677A patent/JP6792294B2/ja active Active
- 2016-05-23 EP EP19185833.1A patent/EP3590518B1/en active Active
- 2016-05-23 WO PCT/US2016/033817 patent/WO2016196062A1/en not_active Ceased
- 2016-05-23 RU RU2017145940A patent/RU2017145940A/ru not_active Application Discontinuation
- 2016-05-23 ES ES16727089T patent/ES2752063T3/es active Active
- 2016-05-23 MX MX2017015294A patent/MX381587B/es unknown
- 2016-05-23 US US15/162,535 patent/US9993495B2/en active Active
-
2017
- 2017-11-26 IL IL255903A patent/IL255903B/en unknown
-
2018
- 2018-05-24 US US15/989,055 patent/US10111899B2/en active Active
- 2018-09-25 US US16/141,828 patent/US10369168B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017145940A3 (https=) | 2019-11-26 |
| JP2018521011A (ja) | 2018-08-02 |
| US9993495B2 (en) | 2018-06-12 |
| EP3302502A1 (en) | 2018-04-11 |
| CA2987237A1 (en) | 2016-12-08 |
| US20160346312A1 (en) | 2016-12-01 |
| AU2016270782B2 (en) | 2021-08-12 |
| RU2017145940A (ru) | 2019-07-02 |
| KR102779525B1 (ko) | 2025-03-12 |
| ES2752063T3 (es) | 2020-04-02 |
| EP3590518B1 (en) | 2024-03-20 |
| HK1251471A1 (zh) | 2019-02-01 |
| CN107708706A (zh) | 2018-02-16 |
| MX381587B (es) | 2025-03-12 |
| US10369168B2 (en) | 2019-08-06 |
| DK3302502T3 (da) | 2019-10-28 |
| US20190151345A1 (en) | 2019-05-23 |
| KR20180021700A (ko) | 2018-03-05 |
| EP3590518A1 (en) | 2020-01-08 |
| EP3302502B1 (en) | 2019-08-28 |
| WO2016196062A1 (en) | 2016-12-08 |
| AU2016270782A1 (en) | 2017-12-07 |
| JP6792294B2 (ja) | 2020-11-25 |
| US10111899B2 (en) | 2018-10-30 |
| US20180264023A1 (en) | 2018-09-20 |
| IL255903A (en) | 2018-01-31 |
| MX2017015294A (es) | 2018-02-19 |
| NZ737488A (en) | 2024-12-20 |
| IL255903B (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2987696T3 (es) | Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón | |
| EP4286009A2 (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| EP3419643A1 (en) | Smc combination therapy for the treatment of cancer | |
| JP2025120300A (ja) | 合成ｒｉｇ－ｉ様受容体アゴニスト | |
| CN105209047A (zh) | 用于癌症治疗的gla单一疗法 | |
| JP7321489B2 (ja) | がん免疫アジュバント | |
| KR20170100033A (ko) | 분지형 및 선형 키메라 화합물, 폴리뉴클레오티드, 그것들의 용도 및 제조 방법 | |
| JP6536964B2 (ja) | 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用 | |
| ES2702618B2 (es) | Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica. | |
| WO2020081398A1 (en) | Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer | |
| HK40020378A (en) | Polynucleotide toll-like receptor 9 agonists for treating cancer of the lung | |
| US12128099B2 (en) | Myxoma virus compositions and methods of use | |
| US20240252563A1 (en) | Cancer treatments | |
| WO2024153142A1 (zh) | CpG寡核苷酸及其应用 | |
| HK40097178A (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| HK1255016A1 (en) | Methods of treating solid or lymphatic tumors by combination therapy |